Acta Oncol Tur.. Ahead of Print: AOT-32068

Screening for Distress During COVID-19 Outbreak Among Hematopoietic Stem Cell Transplantation Survivors

Olga Meltem Akay¹, Sait Berk Barlas¹, Þirin Zelal Þahin Týrnova¹, Hayrunnisa Albayrak², Özgür Mehtap², Deniz Gören Þahin³, Osman Kara⁴, Cafer Adýgüzel⁴, Gülkan Özkan⁵, Hasan Atilla Özkan⁵, Ünal Ataþ⁶, Orhan Kemal Yücel⁶, Ozan Salim⁶, Melis Mutlu⁷, Arzu Baygül Eden^8
1Department of Hematology, Koç University School of Medicine
²Department of Hematology, Kocaeli University School of Medicine
³Department of Hematology, Bilim University School of Medicine
⁴Department of Hematology, Bahçeþehir University Medical Park Göztepe Hospital
⁵Department of Hematology, Yeditepe University School of Medicine
⁶Department of Hematology, Akdeniz University School of Medicine
⁷Department of Hematology, Sanko University School of Medicine
⁸Department of Bioistastics, Koc University School of Medicine

INTRODUCTION: Introduction: The COVID-19 pandemic has led to an increase in mental distress, such as anxiety symptoms and depression. Our objective was to evaluate the impact of COVID-19 on the anxiety and depression levels of the hematopoietic stem cell transplant (HSCT) recipients comprising a highly immunocompromised group with a greater risk of infection and prolonged isolation.
METHODS: Materials and Methods: The Hospital Anxiety and Depression Scale (HADS) was administered to 203 HSCT recipients, a concurrent group of 69 hematological cancer patients receiving standard chemotherapy, and a group of 82 healthy controls.
RESULTS: Results: Median HADS Anxiety score was 6 (interquartile range (IQR) 2-9) for 203 HSCT patients, 7 (IQR 4-9) for 82 healthy controls, and 6 (IQR 4-8) for 69 patients with a hematological malignancy receiving chemotherapy. There was a statistically significant difference in HADS Anxiety scores between HSCT patients, chemotherapy patients, and healthy controls (p=0.019). The median HADS Depression score was 5 (IQR 3-8) for HSCT patients, 5 (IQR 3-8) for healthy controls, and 5 (3-8) for patients with a hematological malignancy receiving chemotherapy. There were no significant differences in HADS Depression scores in between groups (P = 0.549). There were no statistically significant differences in HADS Anxiety and HADS Depression scores between patients undergoing autologous and allogeneic SCT (p=0.245). Anxiety levels were higher in young patients (p=0.003), while none of the other clinical variables were associated with anxiety and depression rates.
DISCUSSION AND CONCLUSION: Conclusion: Our study revealed that the COVID-19 pandemic did not have a negative impact on the levels of depression and anxiety in HSCT recipients.

Keywords: COVID-19, anxiety, depression, hematopoietic stem cell transplantation

---

KOVÝD-19 Salgýný Sýrasýnda Hematopoietik Kök Hücre Nakli Hastalarýnda Distres Taramasý

Olga Meltem Akay¹, Sait Berk Barlas¹, Þirin Zelal Þahin Týrnova¹, Hayrunnisa Albayrak², Özgür Mehtap², Deniz Gören Þahin³, Osman Kara⁴, Cafer Adýgüzel⁴, Gülkan Özkan⁵, Hasan Atilla Özkan⁵, Ünal Ataþ⁶, Orhan Kemal Yücel⁶, Ozan Salim⁶, Melis Mutlu⁷, Arzu Baygül Eden^8
1Koç Üniversitesi Týp Fakültesi, Hematoloji Bilim Dalý
²Kocaeli Üniversitesi Týp Fakültesi, Hematoloji Bilim Dalý
³Bilim Üniversitesi Týp Fakültesi, Hematoloji Bilim Dalý
⁴Bahçeþehir Üniversitesi Medical Park Göztepe Hastanesi, Hematoloji Bölümü
⁵Yeditepe Üniversitesi Týp Fakültesi, Hematoloji Bilim Dalý
⁶Akdeniz Üniversitesi Týp Fakültesi, Hematoloji Bilim Dalý
⁷Sanko Üniversitesi Týp Fakültesi, Hematoloji Bilim Dalý
⁸Koç Üniversitesi Týp Fakültesi, Biyoistatistik Anabilim Dalý

GÝRÝÞ ve AMAÇ: Giriþ: KOVÝD-19 salgýný, anksiyete belirtileri ve depresyon gibi mental sýkýntýlarýn artmasýna neden olmuþtur. Amacýmýz, yüksek enfeksiyon riski ve uzun süreli izolasyona sahip, ciddi düzeyde immünsüpresif bir grup olan hematopoietik kök hücre nakli (HKHN) alýcýlarýnýn anksiyete ve depresyon düzeyleri üzerine KOVÝD-19'un etkisini deðerlendirmekti.
YÖNTEM ve GEREÇLER: Gereç ve Yöntemler: Hastane Anksiyete ve Depresyon Ölçeði (HAD), 203 HKHN alýcýsýna, standart kemoterapi alan 69 hematolojik kanser hastasýndan oluþan bir gruba ve 82 saðlýklý kontrolden oluþan bir gruba uygulandý.
BULGULAR: Bulgular: Medyan HAD Anksiyete skoru; 203 HKHN hastalarý için 6 (çeyrekler arasý aralýk (IQR) 2-9), 82 saðlýklý kontrol için 7 (IQR 4-9) ve kemoterapi alan hematolojik malignitesi olan 69 hasta için 6 (IQR 4-8) idi. HKHN hastalarý, kemoterapi hastalarý ve saðlýklý kontroller arasýnda HAD Anksiyete skoru açýsýndan istatistiksel olarak anlamlý bir farklýlýk saptandý (p=0,019). Medyan HAD Depresyon skoru; HKHN hastalarý için 5 (IQR 3-8), saðlýklý kontroller için 5 (IQR 3-8) ve kemoterapi alan hematolojik malignitesi olan hastalar için 5 (3-8) idi. Gruplar arasýnda HAD Depresyon puanlarý açýsýndan anlamlý bir farklýlýk saptanmadý (P = 0,549). HAD Anksiyete ve HAD Depresyon skorlarý, otolog ve allojenik KHN uygulanan hastalar arasýnda istatistiksel olarak anlamlý deðildi (p=0,245). Genç hastalarda anksiyete düzeyi daha yüksek iken (p=0,003), diðer klinik deðiþkenlerin hiçbiri anksiyete ve depresyon düzeyleri ile iliþkili deðildi.
TARTIÞMA ve SONUÇ: Sonuç: Çalýþmamýz, KOVÝD-19 salgýnýnýn, HKHN alýcýlarýnýn depresyon ve anksiyete seviyeleri üzerine olumsuz bir etkisi olmadýðýný ortaya koydu.

Anahtar Kelimeler: KOVÝD-19, anksiyete, depresyon, hematopoetik hücre nakli

---